view in publisher's site

Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis

Highlights•20 specific anti-guselkumab monoclonal antibodies were generated and characterized.•An accurate and precise ELISA to quantify guselkumab was developed.•The guselkumab ELISA was validated in moderate-to-severe psoriasis patients.•Two different ELISAs to detect anti-guselkumab antibodies were developed.AbstractTherapeutic drug monitoring, which is the measurement of drug concentrations in the blood, is a useful tool to guide clinical decision-making and treatment adjustments, on the condition that drug concentrations are correlated with treatment response. For guselkumab, an anti-IL-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis, such a concentration-response relationship could not yet be determined as no commercial assays for the quantification of this drug or antibodies against this drug are available. Therefore, the aim of this study was to develop and validate immunoassays for the quantification of guselkumab and anti-guselkumab antibodies according to the guidelines of the European Medicines Agency (EMA). A diverse panel of 20 highly specific anti-guselkumab monoclonal antibodies (MA-GUS) was generated of which eight revealed a neutralizing capacity of ≥65 %. At least seven different antibody clusters were identified based on their epitope binning profile. Using MA-GUS9F6 as the capture antibody and MA-GUS12G12 as the detection antibody, an ELISA was developed with a dose-response curve ranging from 0.08 to 5 ng/mL. The assay was specific, selective and could accurately and precisely quantify guselkumab concentrations in spiked healthy control serum and serum from guselkumab-treated psoriasis patients with a cut-off for quantification of 0.014 μg/mL. The presence of IL-23 in physiological concentrations or of non-neutralizing antibodies did not impact the quantification of guselkumab, while the presence of neutralizing antibodies did. Using MA-GUS12A9 as a calibrator, two anti-guselkumab antibody assays were developed to detect anti-guselkumab antibodies, which differ in the threshold for detection and quantification and the tolerance to the presence of guselkumab. Together, these validated immunoassays are essential to establish a concentration-response relationship and will allow the future implementation of therapeutic drug monitoring in moderate-to-severe psoriasis patients receiving guselkumab treatment.

توسعه و اعتبار سنجی of برای نظارت بر guselkumab و آنتی‌بادی ضد guselkumab در بیماران با پسوریازیس متوسط

ترجمه شده با


پر ارجاع‌ترین مقالات مرتبط:

  • مقاله Analytical Chemistry
  • ترجمه مقاله Analytical Chemistry
  • مقاله شیمی تجزیه
  • ترجمه مقاله شیمی تجزیه
  • مقاله Pharmaceutical Science
  • ترجمه مقاله Pharmaceutical Science
  • مقاله علوم دارویی
  • ترجمه مقاله علوم دارویی
  • مقاله Spectroscopy
  • ترجمه مقاله Spectroscopy
  • مقاله اسپکتروسکوپی
  • ترجمه مقاله اسپکتروسکوپی
  • مقاله Clinical Biochemistry
  • ترجمه مقاله Clinical Biochemistry
  • مقاله بیوشیمی بالینی
  • ترجمه مقاله بیوشیمی بالینی
  • مقاله Drug Discovery
  • ترجمه مقاله Drug Discovery
  • مقاله کشف دارو
  • ترجمه مقاله کشف دارو
سفارش ترجمه مقاله و کتاب - شروع کنید

با استفاده از افزونه دانلود فایرفاکس چکیده مقالات به صورت خودکار تشخیص داده شده و دکمه دانلود فری‌پیپر در صفحه چکیده نمایش داده می شود.